双歧杆菌活菌制剂对婴幼儿腹泻疗效的影响分析

目的探讨双歧杆菌活菌制剂对婴幼儿腹泻疗效的影响。方法选择腹泻患儿120例,随机分为观察组和对照组各60例。对照组给予思密达治疗,观察组给予双歧杆菌活菌制剂。结果观察组的总有效率明显高于对照组,两组总有效率比较差异有显著性意义(P<0.05)。结论双歧杆菌活菌制剂治疗婴幼儿腹泻疗效满意,值得借鉴。     

双歧杆菌三联活菌对婴幼儿抗生素相关性腹泻的预防作用

目的:探讨双歧杆菌三联活菌对不同年龄组婴幼儿抗生素相关性腹泻(AAD)的预防作用。方法:下呼吸道感染患儿255例,按年龄分为1～12月组120例与12～36月组135例,组内再随机分成预防组与对照组。预防组在抗生素治疗同时服用双歧杆菌三联活菌,对照组抗生素治疗开始不服用双歧杆菌三联活菌,出现腹泻后加服该药,比较两组腹泻发生率的差异。同时比较不同年龄组婴幼儿服用双歧杆菌三联活菌对AAD预防作用的差异。结果:1～12月预防组62例发生腹泻11例,对照组58例发生腹泻23例,差异有统计学意义(P<0.05);12～36月预防组79例发生腹泻3例,对照组56例发生腹泻14例,差异有统计学意义(P<0.05)。对照组两个年龄组间比较,差异无统计学意义(P>0.05);预防组两个年龄组间比较,差异有统计学意义(P<0.05)。结论:双歧杆菌三联活菌可降低婴幼儿AAD的发病率。     

双歧乐对双歧杆菌增殖的影响

本文介绍了唐山市生物化学制药厂生产的双歧乐活性的检验方法和结果.用含有双歧乐的培养基对双歧杆菌进行了定性、定量观察.其结果表明,唐山市生物化学制药厂生产的双歧乐对双歧杆菌有明显的促进作用;在双歧杆菌制剂的生产、实验过程中,如果添加一定量的双歧乐,不仅可以提高双歧杆菌收率,而且还可以缩短菌种发酵时间.     

双歧杆菌活菌与蒙脱石散对小儿腹泻的治疗效果评价

目的分析双歧杆菌活菌与蒙脱石散对小儿腹泻的治疗效果。方法将我院收治的80例腹泻患儿纳入本次实验,入选病例均来自2016年3月至2017年9月,按照随机数字表法将其分为实验组、对照组,各40例,两组均给予常规治疗,对照组在此基础上应用蒙脱石散治疗,实验组采取蒙脱石散+双歧杆菌活菌治疗,对比两种治疗方案的疗效。结果实验组患儿治疗总有效率(92.5%)较对照组(75.0%)更高,止泻时间、退热时间、呕吐缓解时间、腹痛缓解时间、大便恢复正常时间较对照组更短,IgA、IgG、CD4/CD8均较对照组更高,IL-6、TNF-α均较对照组更低,组间比较P <0.05。结论对腹泻患儿给予双歧杆菌活菌联合蒙脱石散治疗可获得理想的疗效,能快速缓解其各项临床症状,改善免疫功能。     

双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效分析

目的探讨双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效分析。方法选取98例腹泻患儿,按数字表法分为两组,各49例,观察组在常规治疗的基础上给予双歧杆菌四联活菌片联合蒙脱石散治疗,对照组仅给予常规治疗的基础上给予蒙脱石散治疗。结果观察组显效48.98%、有效42.86%、无效8.16%、总有效率91.84%,临床疗效明显高于对照组(P<0.05);观察组患儿体温恢复时间(20.3±4.7)h、大便次数恢复时间(1.8±0.7)d、大便性状恢复时间(2.8±0.9)d,均明显低于对照组(P<0.05)。结论双歧杆菌活菌联合蒙脱石散治疗小儿腹泻疗效显著,能快速改善患儿临床症状,值得临床推广。     

双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效分析

目的分析双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效。方法选取我院2016年4月至2017年1月收治的90例小儿腹泻患儿,采用随机分组的方式分为对照组与观察组,各组人数均为45例。对照组采用蒙脱石散治疗,观察组采用双歧杆菌活菌联合蒙脱石散治疗,治疗1周后比对两组患儿的恢复情况。结果观察组治疗的总有效率明显高于对照组,P <0.05,具有统计学意义。观察组患儿发热消退时间、大便恢复时间、呕吐缓解时间等均短于对照组,P <0.05,具有统计学意义。结论采用双歧杆菌活菌联合蒙脱石散治疗小儿腹泻疗效显著,患儿的恢复时间较短,值得临床推广。     

双歧杆菌三联活菌防治早产儿黄疸临床观察

目的探讨双歧杆菌三联活菌胶囊防治早产儿黄疸的临床效果。方法 54例早产儿随机分为治疗组28例和对照组26例,生后12 h内治疗组在常规治疗的同时加服双歧杆菌三联活菌胶囊(210 mg/粒,2次/d)。结果对照组早产儿黄疸消退的平均时间为生后(17.92±3.37)d,治疗组早产儿黄疸消退的平均时间为生后(15.75±3.33)d,治疗组早产儿黄疸消退时间短于对照组(P<0.05)。结论早期口服双歧杆菌三联活菌胶囊对早产儿黄疸的防治有一定效果,且可缩短住院时间,降低住院费用,无毒副作用,值得推广。     

双歧杆菌活菌与蒙脱石散对小儿腹泻的治疗效果评价

目的探究小儿腹泻采取双歧杆菌活菌、蒙脱石散治疗的临床效果。方法将2014年7月至2017年6月我院经诊断确诊为小儿腹泻的患儿80例纳为本次参研的对象,依照随机数字表法均分为A组与B组,前者行蒙脱石散单药治疗;后者行在前者治疗的基础上加用双歧杆菌活菌治疗。治疗后统计比较两组临床症状改善用时及疗效的优劣。结果 B组临床症状消失的时间均短于A组,治疗总有效率92.5%则高于A组75%,P<0.05,各组数据比较后差异性显著,有统计学意义。结论小儿腹泻临床治疗中应用双歧杆菌活菌及蒙脱石散联合治疗的效果显著,不仅能快速改善患儿临床症状,还可提高疗效,促进患儿尽快康复,建议推广。     

双歧杆菌活菌制剂与蒙脱石散对小儿腹泻的近期疗效评价

目的:评价双歧杆菌活菌制剂与蒙脱石散对小儿腹泻的近期疗效。方法:选取2015年3月—2016年3月期间收治的小儿腹泻患者87例,将其随机分为观察组(44例)及对照组(43例);对照组患者给予蒙脱石散治疗,观察组患者在对照组基础上加用双歧杆菌活菌制剂治疗,比较两组患者治疗后与腹泻相关症状的改善时间(包括体温复常、呕吐缓解、腹痛缓解及大便性状复常时间),以及治疗的总有效率。结果:观察组患儿治疗后与腹泻相关症状改善时间均明显短于对照组(P<0.05),观察组患儿的治疗总有效率明显高于对照组(P<0.05)。结论:双歧杆菌活菌制剂与蒙脱石散联用于治疗小儿腹泻的近期疗效较为显著,改善了患儿临床症状。     

双歧杆菌三联活菌胶囊联合四磨汤对儿童厌食症的治疗分析

目的探讨双歧杆菌三联活菌胶囊联合四磨汤对儿童厌食症的治疗效果。方法选取96例厌食症患儿按随机数字表法分成观察组和对照组,各48例。对照组采用四磨汤进行治疗,观察组在对照组的基础上给予双歧杆菌三联活菌胶囊。对比两组的治疗效果及治疗前、后腹部皮下脂肪厚度。结果观察组治疗的总有效率明显较对照组高,差异有统计学意义(P<0.05);两组治疗前皮下脂肪厚度差异无统计学意义(P>0.05);观察组治疗后皮下脂肪厚度明显高于对照组,差异有统计学意义(P<0.05)。结论双歧杆菌三联活菌胶囊联合四磨汤可有效的提高对儿童厌食症的治疗效果。     

双歧杆菌对应激模型大鼠肠道通透性的影响

目的:研究双歧杆菌对应激模型大鼠肠道通透性的影响及其与蒙脱石散联用的协同作用。方法:取SD大鼠50只随机均分为正常对照组、模型对照组、双歧杆菌干预组(2×108cfu)、蒙脱石散干预组(0.6 g.kg-1)及其联合干预组(双歧杆菌2×108cfu+蒙脱石散0.6 g.kg-1),每日灌胃给药1次,连续给药7 d,后4组每日给药后以避水压力模型(WAS)方法建立大鼠应激模型。第8天各组分别灌胃给予探针药物甘露醇80 mg、三氯蔗糖60 mg,检测各组大鼠给药后5、24 h尿液中甘露醇、三氯蔗糖的量及其比值,以评价肠道通透性。实验结束处死大鼠,检测各组大鼠血清中促肾上腺皮质激素释放因子(CRF)和促肾上腺皮质激素(ACTH)的含量。结果:与正常对照组比较,模型对照组大鼠24 h尿液中甘露醇的量及血清中CRF、ACTH含量均明显升高(P<0.05);与模型对照组比较,双歧杆菌干预组和联合干预组ACTH含量均明显降低(P<0.05),其余指标均有降低,但没有统计学意义。结论:双歧杆菌对应激模型大鼠的肠道通透性有影响,其与蒙脱石散联用对应激所致的肠道屏障功能紊乱无协同作用。     

双歧杆菌联合左卡尼汀对菌群失调腹泻模型大鼠肠道菌群的影响

目的:研究双歧杆菌联合左卡尼汀对菌群失调腹泻摸型大鼠肠道菌群的影响.方法:将30只SD大鼠随机分为空白对照组、摸型组、益生菌组(双歧杆菌三联活菌肠溶胶囊70 mg/mL)、左卡尼汀组(左卡尼汀注射液50 mg/mL)和左卡尼汀+益生菌组(左卡尼汀注射液50 mg/mL+双歧杆菌三联活菌肠溶胶囊70 mg/mL).除空白...     

体外培养人眼结膜上皮细胞

目的探索体外分离培养人眼结膜上皮细胞的方法。方法用组织块培养法培养人眼结膜上皮组织，分别种植于培养皿及处理过的羊膜上，培养2周，观察结膜上皮细胞的生长特性。结果接种在培养皿的结膜上皮约6 d组织块之间可融合成膜状，细胞为单层上皮细胞。接种在羊膜上的结膜组织生长较慢，约2周组织块之间可互相连接，融合成膜状，细胞为复层上皮细胞。免疫组化鉴定，结膜上皮细胞CK13染色阳性。结论组织块培养法是人眼结膜上皮细胞培养的较好方法，种植在羊膜上可获得复层上皮细胞。     

金双歧联合思密达治疗小儿腹泻疗效观察

目的:探讨联合应用金双歧和思密达治疗小儿腹泻的疗效。方法:选取2013年2月至2014年2月于我院儿科门诊就诊的120例腹泻患者为观察对象。随机将患者分为观察组和对照组,每组各60例。对照组予常规治疗,观察组在常规治疗的基础上采用金双歧与思密达联合治疗。3 d后观察疗效。结果:观察组患者临床症状改善时间显著短于对照组(P<0.05)。总有效率观察组为96.67%,对照组为73.33%,2组比较有显著性差异(P<0.05)。2组患者在治疗过程中均未出现明显的不良反应。结论:金双歧和思密达协同治疗小儿腹泻效果确切,值得临床推广应用。     

双歧杆菌四联活菌对儿童支气管肺炎症状和持续时间的影响

目的:观察双歧杆菌四联活菌对儿童支气管肺炎症状和持续时间的影响.方法:2010年1月~2010年12月本院儿科就诊的小儿支气管肺炎患儿160例,随机分为治疗组和对照组各80例.对照组进行常规基础治疗,治疗组在常规治疗的基础上加用双歧杆菌四联活菌,给药剂量:<6个月,0.5 g/次,2次/d;6个月~1岁,1.0 g/次...     

Binding Studies on Isolated Porcine Small Intestinal Mucosa and in vitro Toxicity Studies Reveal Lack of Effect of C. perfringens Beta-Toxin on the Porcine Intestinal Epithelium

Beta-toxin (CPB) is the essential virulence factor of C. perfringens type C causing necrotizing enteritis (NE) in different hosts. Using a pig infection model, we showed that CPB targets small intestinal endothelial cells. Its effect on the porcine intestinal epithelium, however, could not be adequately investigated by this approach. Using porcine neonatal jejunal explants and cryosections, we performed in situ binding studies with CPB. We confirmed binding of CPB to endothelial but could not detect binding to epithelial cells. In contrast, the intact epithelial layer inhibited CPB penetration into deeper intestinal layers. CPB failed to induce cytopathic effects in cultured polarized porcine intestinal epithelial cells (IPEC-J2) and primary jejunal epithelial cells. C. perfringens type C culture supernatants were toxic for cell cultures. This, however, was not inhibited by CPB neutralization. Our results show that, in the porcine small intestine, CPB primarily targets endothelial cells and does not bind to epithelial cells. An intact intestinal epithelial layer prevents CPB diffusion into underlying tissue and CPB alone does not cause direct damage to intestinal epithelial cells. Additional factors might be involved in the early epithelial damage which is needed for CPB diffusion towards its endothelial targets in the small intestine.     

In-vitro Cell Culture Models of the Nasal Epithelium: A Comparative Histochemical Investigation of Their Suitability for Drug Transport Studies

Purpose. To evaluate different in-vitro cell culture models for their suitability to study drug transport through cell monolayers. Methods. Bovine turbinate cells (BT; ATCC CRL 1390), human nasal septum tumor cells (RPMI, 2650; ATCC CCL 30), and primary cell cultures of human nasal epithelium were characterized morphologically and histochemically by their lectin binding properties. The development of tight junctions in culture was monitored by actin staining and transepithelial electrical resistance measurements. Results. The binding pattern of thin-sections of excised human nasal respiratory epithelium was characterized using a pannel of fluorescently-labelled lectins. Mucus in goblet cells was stained by PNA, WGA and SBA, demonstrating the presence of terminal N-acetylglucosamine, N-acetylgalactosamine and galactose residues respectively in the mucus of human nasal cells. Ciliated cells revealed binding sites for N-acetylglucosamine, stained by WGA, whereas Con A, characteristic for mannose moieties, labelled the apical cytoplasm of epithelial cells. Binding sites for DBA were not present in this tissue. Comparing three different cell culture models: BT, RPMI 2650, and human nasal cells in primary culture using three lectins (PNA, WGA, Con A) as well as intracellular actin staining and transepithelial electrical resistance measurements we found, that only human nasal epithelial cells in primary culture showed differentiated epithelial cells, ciliated nasal cells and mucus producing goblet cells, which developed confluent cell monolayers with tight junctions. Conclusions. Of the in-vitro cell culture models studied, only human nasal cells in primary culture appears to be suitable for drug transport studies.     

Intestinal bacterial colonisation and translocation in C3H/HeJ conventional mice fed a unique dose of live or dead Bifidobacterium breve C50

The efficiency and safety of use of Bifidobacterium breve C50 (BbC50), a potential probiotic, was assessed as regards intestinal microbial colonisation and bacterial translocation. A suspension of BbC50, containing 1-5 to 107-108 live bacteria, was fed to C3H/HeJ mice. The passage of live BbC50 was not demonstrated by culture either in the intestine or extra-intestinal organs. However, mice receiving the highest dose of live bacteria harbored more lactobacilli and less Bacteroides fragilis group in the cecum and colon when compared to control mice. Translocation of lactobacilli observed in the control group was not regulated by Bb50 feeding. Indeed, the spleen was significantly more frequently contaminated in mice fed BbC50, whatever the dose of live bacteria. The kidneys were also significantly more contaminated with lactobacilli in mice fed the highest dose of live Bb50. Moreover, higher dose of live BbC50 was associated with greater number of extra-intestinal contaminated organs. To conclude, BbC50 feeding induced a favorable balance in the mouse intestinal flora and was never found translocating, demonstrating its efficiency and safety of use. However, BbC50 seemed to interfere with the ability of lymphoid organs (e.g. the spleen) to eliminate translocating lactobacilli.     

双歧杆菌四联活菌片联合蒙脱石散对小儿轮状病毒性肠炎的治疗作用观察

目的观察双歧杆菌四联活菌片联合蒙脱石散治疗小儿轮状病毒性肠炎的疗效。方法选择2010年8月至2012年12月在本院住院的162例诊断为轮状病毒性肠炎患儿,随机分为观察组和对照组,观察组92例,对照组70例,两组患儿均给予合理补液纠正水电解质紊乱、利巴韦林抗病毒,及进食指导等基础治疗,观察组在此基础上加用双歧杆菌四联活菌片、蒙脱石散,治疗期间观察两组患儿大便次数、性状、有无呕吐及脱水情况,以及有无不良反应。结果观察组总有效率90.22%,对照组为74.29%,χ2=7.26,P〈0.05,差异有统计学意义,且未发现明显不良反应。结论双歧杆菌四联活菌片联合蒙脱石散对轮状病毒性肠炎有较好的治疗作用,且无明显不良反应,值得临床推广。